RxDoctor Payments Data

Kenneth Seres, MD

Gastroenterology · Oklahoma City, OKNPI 1871633404

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 631 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 36.1% of the total. Reporting peaked in 2022 at $2,256 and has fallen 69.2% since, to $694 in 2024.

$9,437in general payments, 2019–2025

Across 631 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$975
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$820
  • Takeda Pharmaceuticals U.S.A., Inc.$700
  • Pfizer$346
  • Bristol Myers Squibb$284
  • plus $3K from 29 others
$15,650in research payments, 2019–2025

Across 3 payments — averaging $5216.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Covidien LP$16K

What the payments were for

  • Food & beverage$9,411100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,437 in reported general payments places this provider in the 75th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$112,330
Medicare patients
458
Services billed
1,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab19$129,813
LinzessLinaclotide13$12,752
Mesalamine24$8,229
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates66$4,087
Mesalamine ErMesalamine17$4,073
Omeprazole129$4,004
Pantoprazole Sodium83$1,413
Ursodiol24$1,305
Budesonide DrBudesonide13$1,240
PrevaliteCholestyramine12$1,130
Sucralfate29$1,046
Famotidine28$734
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl39$699
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl43$683
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine24$595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,407$12,75213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 133 gastroenterology providers in Oklahoma.

Other gastroenterology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →